Next Phase Newsletter

A multi family office based in Singapore and California invests in early-stage technology companies from pre-Series A to Series B, but has occasionally participated in later financing rounds. The firm’s typical allocation size ranges from $500K to $5M, but the firm has invested as little as $100K and as much as $15M. The firm is looking to make 3-5 investments per year with a preference for US-based companies especially in New York or Silicon Valley. However, the firm has made some investments in Asia and will look globally for innovative technologies.

For companies earlier than a Series B, the firm’s work as a VC is identical to that of any other leading VC, and the getting global element has more to do with helping founders get knowledgeable about global opportunities. At the Series B stage, market entry strategies become more relevant and the firm can help with both its partners’ experience and its networks with governments, enterprises and consumers.

The firm is most interested in tech-enabled startups and will consider digital health/healthcare IT start-ups within the life sciences sector. The firm looks for companies with an established product and some market traction. Within tech-enabled start-ups, the firm has primarily focused on companies with enterprise SaaS, consumer subscription, and marketplace business models.

The primary focus for the firm is finding management teams with which it has strong chemistry, as the firm expects to maintain a close relationship in an active role with its portfolio companies. In earlier stage investments, the focus on the strength of the management team is further magnified (as opposed to market or traction), as the product itself can be expected to change significantly at this stage. Additional founder traits that the firm focuses on include a history of achievement in some area, humility, grit, a growth mindset, and complementary skills (for example, as a hacker or a designer). The firm’s strong preference is to lead or co-lead deals, taking on a board role and working closely with founders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm that was founded in 2004 and is headquartered in Shenzhen, China, provides venture capital and growth capital to growth-stage companies across various industries, including life sciences, Internet, consumables, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally. Companies with a China angle will be a big plus.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in growth-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical company headquartered in Beijing, China is interested in collaborations with biotechnology companies through a variety of collaboration structures including co-development, in/out-licensing, co-promotion, M&A, and joint venture. The company highly prefers products from mature markets like Western Europe and North America.

The firm currently seeking therapeutic opportunities in Oncology and immunotherapy, Respiratory Diseases, Cardiovascular, CNS, Gastrointestinal, and metabolic disease. For small molecule drugs, the company is interested in in-licensing and co-development of assets in phase 2 trials. Earlier assets may be considered but would require closer scrutiny. For biologics, the company is interested in forming joint ventures.

The firm is looking to partner with companies that seek to enter the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Israel focuses on medical and healthcare technology and primarily makes early-stage investments. The firm will also make late stage investments. The firm has raised three funds to date. The firm can allocate as little as a few hundred thousand dollars in seed financing to as much as $3M or more for early to later stage deals. The firm primarily invests in Israeli companies but will consider exceptional opportunities in the US and Europe. The firm is actively seeking new investment opportunities.

The firm seeks to invest in medical devices, HCIT, as well as digital health and connected devices. For medical devices, the firm is opportunistic in terms of subsector and stage of development. The firm primarily invests in early stage devices and will consider devices as early as pre-prototype stage. The firm is focused on the cardiovascular space but is also open to all indications.

The firm seeks to be a hands-on investor and will require a board seat following investment. The firm looks for management teams with strong track records and is comfortable working scientific founders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global venture capital firm based in Menlo Park, California with additional offices worldwide has approximately $3.5 billion in total assets across 10 funds, and the most recent fund closed at over $600 million. The firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies based in the US, India and Israel.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Healthcare IT sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the clinical stage of development, but it also considers preclinical companies one or two years from clinics, as well as near companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A group of private investors dedicated to funding, mentoring, and building new HealthTech startups is based in Buenos Aires, Argentina with additional offices in the US and Europe. The firm makes equity investments from its pilot fund and provides mentorship, technical expertise, and business advisory for seed and early stage companies. The firm is currently seeking new opportunities throughout Latin America.

The firm focuses on companies at the intersection of healthcare and the computer/consumer electronic world. The firm works with concept and venture projects to prove technical and market feasibility, develop sound business models, attract permanent senior management, provide industry contacts, and bring in additional angel or venture capital financing. Current portfolio includes gaming software, wearable devices, and mobile applications. The firm would also consider medical devices that do not require regulatory approval and can get to market quickly. The firm typically avoids therapeutics. The firm’s current portfolio includes 3 companies, all of which involve apps or a device that is integrated with an app.

The firm is looking for top talents in healthcare and information technology with novel, disruptive ideas. The firm’s members are very involved with the investee company by acting as strategic advisors, board members, and board observers to prove technical and market feasibility, develop sound business models, attract permanent senior management, provide industry contacts, and bring in additional angel or venture capital financing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company headquartered in Tokyo, Japan is currently looking for partnering and in-licensing opportunities across the globe.

The firm is currently looking for innovative therapeutics targeting the following priority areas: Thrombosis & Thrombolysis, Pain, Cardio-Renal, Ophthalmology and rare diseases. Other interest areas include metabolic diseases, oncology, organ fibrosis and NAFLD/NASH, neurology, immunology, and mitochondrial disease. The firm is open to biologics or molecular targets, with an increased interest in new platform technologies. The following areas are currently out of focus: hypertension, thrombosis, dyslipidemia, psychiatric diseases, and immunodeficiency.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com